Li Song

Dr. Li Song


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
WLWenfeng Li
Wenfeng Li
FDFang Dai
Fang Dai
SZShan Zhang
Shan Zhang
FXFancheng Xu
Fancheng Xu
ZXZhiyong Xu
Zhiyong Xu
FAFanrong Ai
Fanrong Ai

10 November 2023 in Chemical Engineering Journal
Verified
Journal Article
Closed access
FXFancheng Xu
Fancheng Xu
TDTian Deng
Tian Deng
WLWenfeng Li
Wenfeng Li
YAYufeng Ai
Yufeng Ai
JWJianxin Wu
Jianxin Wu
LSLi Song
Li Song

5 December 2023 in Materials Today Bio
Verified
Journal Article
Open access
YAYufeng Ai
Yufeng Ai
FDFang Dai
Fang Dai
WLWenfeng Li
Wenfeng Li
FXFancheng Xu
Fancheng Xu
HYHanwen Yang
Hanwen Yang
LSLi Song
Li Song
The clinical treatments of bone defects remain a challenge. Hydrogels containing bone marrow mesenchymal stem cells (BMSCs) are extensively used to bone regeneration because of excellent biocompatibility and hydrophilicity. However, the insufficient osteo-induction capacity of the BMSC-loaded hydrogels limits their clinical applications. In this study, bio-active glass (BG) and BMSCs were combined with gelatin methacryloyl (GelMA) to fabricate composite hydrogels via photo-crosslinking, and the regulation of bone regeneration was investigated. In vitro experiments showed that the BG/BMSCs@GelMA hydrogel had excellent cytocompatibility and promoted osteogenic differentiation in BMSCs. Furthermore, the BG/BMSCs@GelMA hydrogel was injected into critical-sized calvarial defects, and the results further confirmed its excellent angiogenetic and bone regeneration capacity. In addition, BG/BMSCs@GelMA promoted the polarization of macrophages towards the M2 phenotype. In summary, this novel composite hydrogel demonstrated remarkable potential for application in bone regeneration due to its immunomodulatory, excellent angiogenetic as well as osteo-induction capacity.

13 April 2023 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
WLWenfeng Li
Wenfeng Li
FXFancheng Xu
Fancheng Xu
FDFang Dai
Fang Dai
TDTian Deng
Tian Deng
YAYufeng Ai
Yufeng Ai
LSLi Song
Li Song
Bioceramic scaffolds used in bone tissue engineering suffer from a low concentration of ceramic particles (<50 wt%), because the high concentration of ceramic particles increases the brittleness of the composite. 3D printed flexible PCL/HA scaffolds with high ceramic particle concentrations (84 wt%) were successfully fabricated in this study. However, the hydrophobicity of PCL weakens the composite scaffold hydrophilicity, which may limit the osteogenic ability to some extent. Thus, as a less time-consuming, less labour intensive, and more cost-effective treatment method, alkali treatment (AT) was employed to modify the surface hydrophilicity of the PCL/HA scaffold, and its regulation of immune responses and bone regeneration were investigated in vivo and in vitro. Initially, several concentrations of NaOH (0.5, 1, 1.5, 2, 2.5, and 5 mol L−1) were employed in tests to determine the appropriate concentration for AT. Based on the comprehensive consideration of the results of mechanical experiments and hydrophilicity, 2 mol L−1 and 2.5 mol L−1 of NaOH were selected for further investigation in this study. The PCL/HA-AT-2 scaffold dramatically reduced foreign body reactions as compared to the PCL/HA and PCL/HA-AT-2.5 scaffolds, promoted macrophage polarization towards the M2 phenotype and enhanced new bone formation. The Wnt/β-catenin pathway might participate in the signal transduction underlying hydrophilic surface-modified 3D printed scaffold-regulated osteogenesis, according to the results of immunohistochemical staining. In conclusion, hydrophilic surface-modified 3D printed flexible scaffolds with high ceramic particle concentrations can regulate the immune reactions and macrophage polarization to promote bone regeneration, and the PCL/HA-AT-2 scaffold is a potential candidate for bone tissue repair.

5 September 2023 in Clinical Radiology
Verified
Journal Article
Closed access
QLQ. Liu
Q. Liu
FDF. Dai
F. Dai
HZH. Zhu
H. Zhu
HYH. Yang
H. Yang
YHY. Huang
Y. Huang
LSLi Song
Li Song

1 May 2018 in Medicine
Verified
Journal Article
Open access
PDF file
HZHaixiao Zou
Haixiao Zou
HYHaili Yang
Haili Yang
YZYuan Zou
Yuan Zou
LLLang Lei
Lang Lei
LSLi Song
Li Song
Lymphomas are the second most common non-epithelial malignant tumors in the oral and maxillofacial region. Non-Hodgkin's lymphoma (NHL) develops at extranodal sites, and cases involving the maxilla account for less than 1% of all NHLs. We describe a case of diffuse large B-cell lymphoma (DLBCL) in the maxilla, and highlight the clinical signs, symptoms, differential diagnosis, and appropriate treatment of DLBCL in the oral cavity and maxillofacial region. A 67-year-old woman was admitted to our surgical department with pain and swelling in her right upper posterior teeth for about six months. She was previously misdiagnosed with periodontal disease and had a history of tooth extraction. Computed tomography (CT) scan revealed extensive osteolysis in the right posterior part of the maxilla with enhanced neoplasm. A solid mass was found upon incisional biopsy, and immunohistochemistry confirmed the diagnosis of DLBCL. The patient was treated with six courses of rituximab, cyclophosphamide, pirarubicin, vincristine, and prednisolone (R-CHOP), followed by external irradiation treatment. The treatment was well tolerated, and the patient is presently alive after two years of follow-up. Non-specific symptoms, such as unclear primary dental pain and unresolved periapical swelling, can make an accurate diagnosis of DLBCL difficult, which frequently lead to delayed diagnosis. A CT or cone beam computed tomography (CBCT) scan of the maxilla and immunohistochemical staining of the biopsy specimen is recommended. Combination therapy including radiotherapy and chemotherapy is the optimal treatment for NHL.